Protagenic Therapeutics

Protagenic Therapeutics EBIT Margin

EBIT Margin (Operating Margin) of Protagenic Therapeutics (PTIX) as of Nov 16, 2026.

EBIT Margin

-

Last updated:

EBIT Margin (Operating Margin) of Protagenic Therapeutics is 2026 - . EBIT Margin (Operating Margin) of Protagenic Therapeutics was 2025 - . It decreases by % lower compared to the previous year.

Protagenic Therapeutics's operating (EBIT) margin stands at -791.8%, down from -14.9% several years earlier.

The Protagenic Therapeutics EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2006
0.08 USD
Jan 1, 2007
-0.15 USD
Jan 1, 2008
-1.03 USD
Jan 1, 2009
-0.42 USD
Jan 1, 2010
-0.56 USD
Jan 1, 2012
-7.92 USD
The Protagenic Therapeutics EBIT Margin history
YEAREBIT MarginYoY
-7.92 %+1,321.45%
-0.56 %+33.34%
-0.42 %-59.37%
-1.03 %+591.45%
-0.15 %-288.85%
0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Protagenic Therapeutics Stock analysis

What does Protagenic Therapeutics do? Protagenic Therapeutics, Inc. develops therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound PT00114 is a synthetic TCAP-1 peptide designed to dampen overactive stress responses. The company also has a portfolio of earlier stage neuropeptides targeting the TCAP pathway in preclinical evaluation. PT00114 has shown pre-clinical efficacy in animal models of depression, anxiety, substance abuse, addiction, and PTSD, including the Saleens test for opioid withdrawal. The company focuses on developing treatments for conditions where current therapies are limited or ineffective. Protagenic's products are developed for pharmaceutical companies and research institutions seeking novel treatments for neuropsychiatric disorders. The target segments include patients suffering from depression, anxiety, PTSD, and substance abuse disorders. The company's lead compound PT00114 and its neuropeptide portfolio are positioned as potential treatments for these conditions, with the aim of addressing unmet medical needs in mental health care. Protagenic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Protagenic Therapeutics stock

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Protagenic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Protagenic Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Protagenic Therapeutics

All Key Metrics — Protagenic Therapeutics